| Literature DB >> 33589835 |
András Lakatos1,2, James P O'Callaghan3, Gabor C Petzold4,5, Alberto Serrano-Pozo6,7, Christian Steinhäuser8, Andrea Volterra9, Giorgio Carmignoto10,11, Carole Escartin12, Elena Galea13,14, Amit Agarwal15, Nicola J Allen16, Alfonso Araque17, Luis Barbeito18, Ari Barzilai19, Dwight E Bergles20, Gilles Bonvento21, Arthur M Butt22, Wei-Ting Chen23, Martine Cohen-Salmon24, Colm Cunningham25, Benjamin Deneen26, Bart De Strooper23,27, Blanca Díaz-Castro28, Cinthia Farina29, Marc Freeman30, Vittorio Gallo31, James E Goldman32, Steven A Goldman33,34, Magdalena Götz35,36, Antonia Gutiérrez37,38, Philip G Haydon39, Dieter H Heiland40,41, Elly M Hol42, Matthew G Holt43, Masamitsu Iino44, Ksenia V Kastanenka45, Helmut Kettenmann46, Baljit S Khakh47, Schuichi Koizumi48, C Justin Lee49, Shane A Liddelow50, Brian A MacVicar51, Pierre Magistretti52,53, Albee Messing54, Anusha Mishra55, Anna V Molofsky56, Keith K Murai57, Christopher M Norris58, Seiji Okada59, Stéphane H R Oliet60, João F Oliveira61,62,63, Aude Panatier60, Vladimir Parpura64, Marcela Pekna65, Milos Pekny66, Luc Pellerin67, Gertrudis Perea68, Beatriz G Pérez-Nievas69, Frank W Pfrieger70, Kira E Poskanzer71, Francisco J Quintana72, Richard M Ransohoff73, Miriam Riquelme-Perez21, Stefanie Robel74, Christine R Rose75, Jeffrey D Rothstein76, Nathalie Rouach77, David H Rowitch2, Alexey Semyanov78,79, Swetlana Sirko80,81, Harald Sontheimer82, Raymond A Swanson83, Javier Vitorica38,84, Ina-Beate Wanner85, Levi B Wood86, Jiaqian Wu87, Binhai Zheng88, Eduardo R Zimmer89, Robert Zorec90,91, Michael V Sofroniew92, Alexei Verkhratsky93,94.
Abstract
Reactive astrocytes are astrocytes undergoing morphological, molecular, and functional remodeling in response to injury, disease, or infection of the CNS. Although this remodeling was first described over a century ago, uncertainties and controversies remain regarding the contribution of reactive astrocytes to CNS diseases, repair, and aging. It is also unclear whether fixed categories of reactive astrocytes exist and, if so, how to identify them. We point out the shortcomings of binary divisions of reactive astrocytes into good-vs-bad, neurotoxic-vs-neuroprotective or A1-vs-A2. We advocate, instead, that research on reactive astrocytes include assessment of multiple molecular and functional parameters-preferably in vivo-plus multivariate statistics and determination of impact on pathological hallmarks in relevant models. These guidelines may spur the discovery of astrocyte-based biomarkers as well as astrocyte-targeting therapies that abrogate detrimental actions of reactive astrocytes, potentiate their neuro- and glioprotective actions, and restore or augment their homeostatic, modulatory, and defensive functions.Entities:
Mesh:
Year: 2021 PMID: 33589835 PMCID: PMC8007081 DOI: 10.1038/s41593-020-00783-4
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 24.884